OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Macrophage-Targeted Lung Delivery of Dexamethasone Improves Pulmonary Fibrosis Therapy via Regulating the Immune Microenvironment
Xiaoqing Sang, Yuanyuan Wang, Zhifeng Xue, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 39

Showing 26-50 of 39 citing articles:

Macrophages and pulmonary fibrosis: a bibliometric and visual analysis of publications from 1990 to 2023
Min Yi, Lifei Wu, Chengfu Xu, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 1

Pathogenesis ofBrucellaepididymoorchitis-game ofBrucelladeath
Jiuwang Yu, Sha Li, Lu Wang, et al.
Critical Reviews in Microbiology (2021) Vol. 48, Iss. 1, pp. 96-120
Closed Access | Times Cited: 10

Biomaterial-mediated intracellular control of macrophages for cell therapy in pro-inflammatory and pro-fibrotic conditions
Tina Tylek, Joanna Wong, Andrew E. Vaughan, et al.
Biomaterials (2024) Vol. 308, pp. 122545-122545
Open Access | Times Cited: 1

Engineering cells or cellular outer membranes as multifaceted vehicles for reinforcing nanomedicine-based pulmonary disease treatment
Nan Wang, Jiahe Wu, Jianqing Gao, et al.
Nano Today (2024) Vol. 58, pp. 102414-102414
Closed Access | Times Cited: 1

"Lipid Nanoparticles for Pulmonary Fibrosis: A Comprehensive Review"
Tushar Kanti Dhara, Sayak Khawas, Neelima Sharma
Pulmonary Pharmacology & Therapeutics (2024) Vol. 87, pp. 102319-102319
Closed Access | Times Cited: 1

Zwitterionic Inhaler with Synergistic Therapeutics for Reprogramming of M2 Macrophage to Pro‐Inflammatory Phenotype
Sung-Won Jung, Sungeun Heo, Yoogyeong Oh, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 22
Open Access | Times Cited: 3

ErbB4 promotes M2 activation of macrophages in idiopathic pulmonary fibrosis
Yu Jiang, Jialin Shi, Junhao Zhou, et al.
Open Life Sciences (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 3

Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis
Dongyang Gao, Wenli Gao, Zhiguang Zhai, et al.
Pharmaceutical Science Advances (2023) Vol. 2, pp. 100030-100030
Open Access | Times Cited: 3

Identification of Genetic Signature Associated With Aging in Pulmonary Fibrosis
Yanjiao Lu, Jinkun Chen, Shanshan Wang, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 7

Development and Validation of the Prognostic Index Based on Inflammation-Related Gene Analysis in Idiopathic Pulmonary Fibrosis
Yanjiao Lu, Jinkun Chen, Kun Tang, et al.
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 6

Future development trend of food-borne delivery systems of functional substances for precision nutrition
Shuwei Luo, Juntao Zhang, Jing Sun, et al.
Advances in food and nutrition research (2024), pp. 385-433
Closed Access

CXCL11 reprograms M2-biased macrophage polarization to alleviate pulmonary fibrosis in mice
Ji Young Kim, Dong-Wook Cho, Jung-Yun Choi, et al.
Cell & Bioscience (2024) Vol. 14, Iss. 1
Open Access

Progress in Understanding the Role and Therapeutic Targets of Polarized Subtypes of Macrophages in Pulmonary Fibrosis
Yan Sun, Hao Xu, Tang Lu, et al.
Cell Biochemistry and Biophysics (2023) Vol. 81, Iss. 4, pp. 673-682
Closed Access

Previous Page - Page 2

Scroll to top